SEG101
CSEG101A2401B
Approved small_molecule active
Quick answer
SEG101 for Sickle cell disease is a Approved program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Sickle cell disease
- Phase
- Approved
- Modality
- small_molecule
- Status
- active